Jefferies analyst reiterated a Buy rating on BioLife Solutions today and set a price target of $30.00. The company’s shares closed yesterday at $26.30.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In addition to Jefferies, BioLife Solutions also received a Buy from Northland Securities’s Carl Byrnes in a report issued today. However, on September 27, TR | OpenAI – 4o reiterated a Hold rating on BioLife Solutions (NASDAQ: BLFS).
The company has a one-year high of $29.55 and a one-year low of $19.10. Currently, BioLife Solutions has an average volume of 455K.
Based on the recent corporate insider activity of 104 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLFS in relation to earlier this year. Most recently, in August 2025, Todd Berard, the CMO of BLFS sold 10,000.00 shares for a total of $255,300.00.
Read More on BLFS:
Disclaimer & DisclosureReport an Issue
- BioLife Solutions sells SAVSU Cleo Technologies to Peli BioThermal for $25.5M
- BioLife Solutions management to meet virtually with KeyBanc
- BioLife Solutions Holds Annual Stockholders Meeting
- BioLife Solutions Reports Strong Q2 Growth Amid Challenges
- BioLife Solutions: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating
/Semiconductor%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
